Charles Riv Labs Intl Inc Financials
This page shows Charles Riv Labs Intl Inc (CRL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash generation remains durable while reported earnings fade, revealing a business shaped more by non-cash charges than sales loss.
Across the last three years, revenue was nearly flat, but operating margin compressed from the mid-teens to0.6% , showing that the earnings problem is cost absorption, not a demand collapse. At the same time, free-cash-flow margin reached12.9% as depreciation and amortization rose to$403M ; lower receivables and inventory versus earlier years also helped cash hold up far better than GAAP profit.
The balance sheet still reflects an acquisition-built model: goodwill is
Total liabilities fell to
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Charles Riv Labs Intl Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Charles Riv Labs Intl Inc has an operating margin of 0.6%, meaning the company retains $1 of operating profit per $100 of revenue. This results in a moderate score of 33/100, indicating healthy but not exceptional operating efficiency. This is down from 5.6% the prior year.
Charles Riv Labs Intl Inc's revenue declined 0.9% year-over-year, from $4.0B to $4.0B. This contraction results in a growth score of 31/100.
Charles Riv Labs Intl Inc carries a low D/E ratio of 0.68, meaning only $0.68 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 88/100, indicating a strong balance sheet with room for future borrowing.
Charles Riv Labs Intl Inc's current ratio of 1.29 is below the typical benchmark, resulting in a score of 21/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Charles Riv Labs Intl Inc has a free cash flow margin of 12.9%, earning a moderate score of 55/100. The company generates positive cash flow after capital investments, but with room for improvement.
Charles Riv Labs Intl Inc generates a -4.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 12/100. This is down from 0.6% the prior year.
Charles Riv Labs Intl Inc scores 2.07, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($7.7B) relative to total liabilities ($3.9B). This signals moderate financial risk that warrants monitoring.
Charles Riv Labs Intl Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Charles Riv Labs Intl Inc generates $-5.11 in operating cash flow ($737.6M OCF vs -$144.3M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Charles Riv Labs Intl Inc earns $0.2 in operating income for every $1 of interest expense ($25.2M vs $107.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Charles Riv Labs Intl Inc generated $4.0B in revenue in fiscal year 2025. This represents a decrease of 0.9% from the prior year.
Charles Riv Labs Intl Inc's EBITDA was $428.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 27.3% from the prior year.
Charles Riv Labs Intl Inc reported -$144.3M in net income in fiscal year 2025. This represents a decrease of 750.1% from the prior year.
Charles Riv Labs Intl Inc earned $-2.91 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1555.0% from the prior year.
Cash & Balance Sheet
Charles Riv Labs Intl Inc generated $518.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 3.4% from the prior year.
Charles Riv Labs Intl Inc held $213.8M in cash against $2.1B in long-term debt as of fiscal year 2025.
Charles Riv Labs Intl Inc had 49M shares outstanding in fiscal year 2025. This represents a decrease of 3.7% from the prior year.
Margins & Returns
Charles Riv Labs Intl Inc's operating margin was 0.6% in fiscal year 2025, reflecting core business profitability. This is down 5.0 percentage points from the prior year.
Charles Riv Labs Intl Inc's net profit margin was -3.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 4.1 percentage points from the prior year.
Charles Riv Labs Intl Inc's ROE was -4.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 5.2 percentage points from the prior year.
Capital Allocation
Charles Riv Labs Intl Inc spent $360.7M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 202.6% from the prior year.
Charles Riv Labs Intl Inc invested $219.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 5.9% from the prior year.
CRL Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $995.8M+0.2% | $994.2M-1.1% | $1.0B-2.6% | $1.0B+4.9% | $984.2M-1.8% | $1.0B-0.7% | $1.0B-1.6% | $1.0B |
| Cost of Revenue | $608.9M | N/A | N/A | N/A | N/A | N/A | $660.7M-1.7% | $672.4M |
| Gross Profit | $189.2M | N/A | N/A | N/A | N/A | N/A | $349.0M-1.3% | $353.7M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $159.4M-18.7% | $196.1M+10.4% | $177.6M-7.3% | $191.5M+7.7% | $177.8M-9.2% | $195.7M-1.8% | $199.2M+17.3% | $169.8M |
| Operating Income | $119.9M+142.3% | -$283.4M-311.8% | $133.8M+33.6% | $100.1M+34.1% | $74.7M+144.5% | -$167.7M-242.8% | $117.4M-22.6% | $151.7M |
| Interest Expense | $26.7M+12.5% | $23.8M-6.4% | $25.4M-15.2% | $30.0M+7.5% | $27.9M-1.2% | $28.2M-6.8% | $30.3M-7.6% | $32.8M |
| Income Tax | -$15.1M+15.0% | -$17.8M-156.3% | $31.6M+69.0% | $18.7M+85.4% | $10.1M+431.8% | -$3.0M-114.5% | $20.9M-17.5% | $25.4M |
| Net Income | -$14.8M+94.6% | -$276.6M-608.2% | $54.4M+4.0% | $52.3M+105.4% | $25.5M+111.9% | -$214.5M-407.9% | $69.7M-26.0% | $94.1M |
| EPS (Diluted) | $-0.30 | N/A | $1.10+3.8% | $1.06+112.0% | $0.50 | N/A | $1.33-23.6% | $1.74 |
CRL Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.7B+8.3% | $7.1B-5.0% | $7.5B-0.6% | $7.6B-0.3% | $7.6B+0.7% | $7.5B-5.9% | $8.0B+0.7% | $7.9B |
| Current Assets | $1.5B+2.9% | $1.4B-5.6% | $1.5B+4.2% | $1.5B-2.4% | $1.5B+7.4% | $1.4B-6.1% | $1.5B-0.3% | $1.5B |
| Cash & Equivalents | $191.8M-10.3% | $213.8M+3.2% | $207.1M+13.3% | $182.8M-20.3% | $229.4M+17.9% | $194.6M-7.4% | $210.2M+17.3% | $179.2M |
| Inventory | $359.7M+20.3% | $299.1M-1.1% | $302.6M+8.2% | $279.6M-3.7% | $290.2M+4.2% | $278.5M-17.1% | $336.2M-3.7% | $349.1M |
| Accounts Receivable | $700.3M-1.2% | $708.9M-3.5% | $734.5M-4.3% | $767.6M+1.4% | $756.6M+5.0% | $720.9M-4.4% | $754.2M-1.1% | $762.2M |
| Goodwill | $3.0B+10.0% | $2.8B-5.4% | $2.9B-0.5% | $2.9B+2.2% | $2.9B+0.9% | $2.8B-8.9% | $3.1B+1.5% | $3.1B |
| Total Liabilities | $4.7B+20.8% | $3.9B-3.4% | $4.1B-2.4% | $4.2B-4.1% | $4.3B+8.0% | $4.0B-3.7% | $4.2B0.0% | $4.2B |
| Current Liabilities | $1.1B-2.4% | $1.1B-0.1% | $1.1B+3.8% | $1.1B+2.8% | $1.1B+5.7% | $994.1M-1.8% | $1.0B+6.8% | $947.5M |
| Long-Term Debt | $2.7B+24.7% | $2.1B-2.2% | $2.2B-6.3% | $2.3B-7.1% | $2.5B+12.1% | $2.2B-3.7% | $2.3B-3.4% | $2.4B |
| Total Equity | $2.9B-7.1% | $3.2B-7.1% | $3.4B+1.6% | $3.4B+5.0% | $3.2B-7.7% | $3.5B-8.5% | $3.8B+1.6% | $3.7B |
| Retained Earnings | $1.4B-1.1% | $1.4B-28.6% | $1.9B+2.9% | $1.9B+2.8% | $1.8B+1.4% | $1.8B-14.6% | $2.1B+3.4% | $2.1B |
CRL Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $41.1M-72.2% | $147.5M-31.0% | $213.8M+4.5% | $204.6M+19.2% | $171.7M+7.7% | $159.4M-36.7% | $251.8M+30.1% | $193.5M |
| Capital Expenditures | $55.9M-37.1% | $89.0M+150.0% | $35.6M+0.8% | $35.3M-40.5% | $59.3M-21.5% | $75.6M+95.3% | $38.7M-1.9% | $39.5M |
| Free Cash Flow | -$14.8M-125.3% | $58.6M-67.1% | $178.2M+5.3% | $169.3M+50.7% | $112.4M+34.2% | $83.7M-60.7% | $213.1M+38.3% | $154.0M |
| Investing Cash Flow | -$407.8M-339.5% | -$92.8M-175.4% | -$33.7M+9.8% | -$37.3M+17.9% | -$45.5M+40.2% | -$76.1M-256.9% | -$21.3M+65.5% | -$61.9M |
| Financing Cash Flow | $347.7M+770.5% | -$51.9M+66.0% | -$152.6M+32.7% | -$226.9M-115.4% | -$105.3M-38.8% | -$75.9M+63.4% | -$207.5M+27.4% | -$285.9M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $208.3M+216863.5% | $96K+3.2% | $93K-98.7% | $7.4M-97.9% | $353.1M+284683.9% | $124K-99.9% | $100.8M+1030.6% | $8.9M |
CRL Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 23.7% | N/A | N/A | N/A | N/A | N/A | 34.6%+0.1pp | 34.5% |
| Operating Margin | 12.0%+40.6pp | -28.5%-41.8pp | 13.3%+3.6pp | 9.7%+2.1pp | 7.6%+24.3pp | -16.7%-28.4pp | 11.6%-3.1pp | 14.8% |
| Net Margin | -1.5%+26.3pp | -27.8%-33.2pp | 5.4%+0.3pp | 5.1%+2.5pp | 2.6%+24.0pp | -21.4%-28.3pp | 6.9%-2.3pp | 9.2% |
| Return on Equity | -0.5%+8.2pp | -8.7%-10.3pp | 1.6%+0.0pp | 1.6%+0.8pp | 0.8%+7.0pp | -6.2%-8.0pp | 1.8%-0.7pp | 2.5% |
| Return on Assets | -0.2%+3.7pp | -3.9%-4.6pp | 0.7%+0.0pp | 0.7%+0.4pp | 0.3%+3.2pp | -2.9%-3.7pp | 0.9%-0.3pp | 1.2% |
| Current Ratio | 1.36+0.1 | 1.29-0.1 | 1.370.0 | 1.36-0.1 | 1.43+0.0 | 1.41-0.1 | 1.48-0.1 | 1.58 |
| Debt-to-Equity | 0.91+0.2 | 0.68+0.0 | 0.64-0.1 | 0.70-0.1 | 0.79+0.1 | 0.65+0.0 | 0.62-0.0 | 0.65 |
| FCF Margin | -1.5%-7.4pp | 5.9%-11.8pp | 17.7%+1.3pp | 16.4%+5.0pp | 11.4%+3.1pp | 8.3%-12.8pp | 21.1%+6.1pp | 15.0% |
Similar Companies
Frequently Asked Questions
What is Charles Riv Labs Intl Inc's annual revenue?
Charles Riv Labs Intl Inc (CRL) reported $4.0B in total revenue for fiscal year 2025. This represents a -0.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Charles Riv Labs Intl Inc's revenue growing?
Charles Riv Labs Intl Inc (CRL) revenue declined by 0.9% year-over-year, from $4.0B to $4.0B in fiscal year 2025.
Is Charles Riv Labs Intl Inc profitable?
No, Charles Riv Labs Intl Inc (CRL) reported a net income of -$144.3M in fiscal year 2025, with a net profit margin of -3.6%.
What is Charles Riv Labs Intl Inc's EBITDA?
Charles Riv Labs Intl Inc (CRL) had EBITDA of $428.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Charles Riv Labs Intl Inc have?
As of fiscal year 2025, Charles Riv Labs Intl Inc (CRL) had $213.8M in cash and equivalents against $2.1B in long-term debt.
What is Charles Riv Labs Intl Inc's operating margin?
Charles Riv Labs Intl Inc (CRL) had an operating margin of 0.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Charles Riv Labs Intl Inc's net profit margin?
Charles Riv Labs Intl Inc (CRL) had a net profit margin of -3.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Charles Riv Labs Intl Inc's return on equity (ROE)?
Charles Riv Labs Intl Inc (CRL) has a return on equity of -4.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Charles Riv Labs Intl Inc's free cash flow?
Charles Riv Labs Intl Inc (CRL) generated $518.5M in free cash flow during fiscal year 2025. This represents a 3.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Charles Riv Labs Intl Inc's operating cash flow?
Charles Riv Labs Intl Inc (CRL) generated $737.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Charles Riv Labs Intl Inc's total assets?
Charles Riv Labs Intl Inc (CRL) had $7.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Charles Riv Labs Intl Inc's capital expenditures?
Charles Riv Labs Intl Inc (CRL) invested $219.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Charles Riv Labs Intl Inc's current ratio?
Charles Riv Labs Intl Inc (CRL) had a current ratio of 1.29 as of fiscal year 2025, which is considered adequate.
What is Charles Riv Labs Intl Inc's debt-to-equity ratio?
Charles Riv Labs Intl Inc (CRL) had a debt-to-equity ratio of 0.68 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Charles Riv Labs Intl Inc's return on assets (ROA)?
Charles Riv Labs Intl Inc (CRL) had a return on assets of -2.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Charles Riv Labs Intl Inc's Altman Z-Score?
Charles Riv Labs Intl Inc (CRL) has an Altman Z-Score of 2.07, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Charles Riv Labs Intl Inc's Piotroski F-Score?
Charles Riv Labs Intl Inc (CRL) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Charles Riv Labs Intl Inc's earnings high quality?
Charles Riv Labs Intl Inc (CRL) has an earnings quality ratio of -5.11x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Charles Riv Labs Intl Inc cover its interest payments?
Charles Riv Labs Intl Inc (CRL) has an interest coverage ratio of 0.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Charles Riv Labs Intl Inc?
Charles Riv Labs Intl Inc (CRL) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.